Evidence map›Paper›PMID 42293289›Full record

ArticleJTO clinical and research reports2026

Lung Adenocarcinoma Developing Pleomorphic Carcinoma With

Satoru Senoo, Kohei Takata, Shunsuke Matsumori, Takahiro Baba, Yuka Sugisaki, Hiroki Omori, Hiroaki Matsuura, Yumi Matsuura, Rika Omote, Eiki Ichihara and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Satoru SenooDepartment of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center, Hiroshima, Japan.
Kohei TakataDepartment of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center, Hiroshima, Japan.
Shunsuke MatsumoriDepartment of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center, Hiroshima, Japan.
Takahiro BabaDepartment of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center, Hiroshima, Japan.
Yuka SugisakiDepartment of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center, Hiroshima, Japan.
Hiroki OmoriDepartment of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center, Hiroshima, Japan.
Hiroaki MatsuuraDepartment of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center, Hiroshima, Japan.
Yumi MatsuuraDepartment of Pathology, Kawasaki Medical School, Okayama, Japan.
Rika OmoteDepartment of Diagnostic Pathology, National Hospital Organization Fukuyama Medical Center, Hiroshima, Japan.
Eiki IchiharaDepartment of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center, Hiroshima, Japan.
Toshiaki OkadaDepartment of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center, Hiroshima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Case: We report a 66-year-old man with advanced lung adenocarcinoma who received multiple lines of systemic therapy and subsequently responded to eighth-line sotorasib but later experienced disease progression. At progression, next-generation sequencing of a metastatic lesion revealed Conclusion:

Indexed as

Case reportERBB3 amplificationKRAS G12C mutationPleomorphic carcinomaSotorasib

Identifiers

PMID42293289
PMCPMC13253119

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.